Department of Pharmacy, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alberta, Canada.
Eur J Pharm Biopharm. 2019 Aug;141:58-69. doi: 10.1016/j.ejpb.2019.05.004. Epub 2019 May 9.
Drug repositioning may be defined as a process when new biological effects for known drugs are identified, leading to recommendations for new therapeutic applications. Niclosamide, present in the Model List of Essential Medicines, from the World Health Organization, has been used since the 1960s for tapeworm infection. Several preclinical studies have been shown its impressive anticancer effects, which led to clinical trials for colon and prostate cancer. Despite high expectations, proof of efficacy and safety are still required, which are associated with diverse biopharmaceutical challenges, such as the physicochemical properties of the drug and its oral absorption, and their relationship with clinical outcomes. Nanostructured systems are innovative drug delivery strategies, which may provide interesting pharmaceutical advantages for this candidate. The aim of this review is to discuss challenges involving niclosamide repositioning for cancer diseases, and the opportunities of therapeutic benefits from nanosctrutured system formulations containing this compound.
药物重定位可以定义为一个过程，在这个过程中，已知药物的新生物学效应被识别，从而导致新的治疗应用建议。尼氯硝唑，世界卫生组织基本药物标准清单中的一种药物，自 20 世纪 60 年代以来就被用于治疗绦虫感染。多项临床前研究表明其具有显著的抗癌作用，这促使人们对结肠癌和前列腺癌进行了临床试验。尽管人们寄予厚望，但仍需要证明其疗效和安全性，这与各种生物制药挑战有关，如药物的理化性质及其口服吸收，以及它们与临床结果的关系。纳米结构系统是一种创新的药物输送策略，可为该候选药物提供有趣的药物优势。本文的目的是讨论涉及尼氯硝唑用于癌症疾病的重定位的挑战，以及包含该化合物的纳米结构系统制剂带来的治疗益处的机会。
